Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on ...

David Epstein, the Seagen CEO who helped sell the company to Pfizer in a blockbuster deal, is back to lead a new startup.

Novartis’ 2.7 billion euro ($2.9 billion) gamble on MorphoSys has hit turbulence. | Novartis’ 2.7 billion euro gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

With the seven-year experience of attending the China International Import Expo, Guan Hong, a senior executive at Novartis China believes CIIE is one of the best windows to introduce new medicines and ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...

ZURICH (Reuters) - Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant ...